Innovent Biologics has received approval from China's National Medical Products Administration (NMPA) for mazdutide for chronic weight management in adults with obesity or overweight14.
Mazdutide, developed in partnership with Eli Lilly, is the first dual glucagon/GLP-1 receptor agonist (GCG/GLP-1 RA) approved globally, representing a new drug class in obesity treatment4.
Mazdutide is an oxyntomodulin analogue, showing not only strong weight loss and glucose-lowering effects but also improvements in waist circumference, blood lipids, blood pressure, uric acid levels, liver enzymes, and insulin sensitivity2.
The approval highlights China's emergence as a source of innovative obesity treatments and reinforces Innovent's position in the metabolic disease market5.
Mazdutide's clinical program includes seven ongoing Phase 3 trials, and it has submitted two NDAs to the NMPA:
for long-term weight management and for glycemic control in type 2 diabetes23.
Sources:
1. https://www.pharmaceutical-business-review.com/news/innovents-mazdutide-china-approval/
2. https://www.prnewswire.com/news-releases/innovent-announces-completion-of-first-participant-dosed-in-the-seventh-phase-3-clinical-trial-glory-osa-of-mazdutide-in-china-302481798.html
3. https://firstwordpharma.com/story/5975891
4. https://www.gurufocus.com/news/2949830/innovent-biologics-inc-ivbiy-secures-nmpa-approval-for-mazdutide-in-china--ivbiy-stock-news
5. https://www.ainvest.com/news/weight-opportunity-innovent-biologics-mazdutide-dominate-china-metabolic-disease-market-2506/